Advances in drug therapy for systemic lupus erythematosus

BMC Medicine

Volumn 8, Issue , 2010, Pages

  Wallace, Daniel J ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 623; ABATACEPT; ABETIMUS; AMG 811; ATACICEPT; BELIMUMAB; BORTEZOMIB; CARFILZUMIB; CELL SURFACE RECEPTOR; CYTOKINE RECEPTOR ANTAGONIST; ECULIZUMAB; EDRATIDE; EFALIZUMAB; EPRATUZUMAB; FOSTAMATINIB; IMMUNOSUPPRESSIVE AGENT; LY 2127399; NNC 0152; OCRELIZUMAB; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RONTALIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

B LYMPHOCYTE; CLINICAL TRIAL (TOPIC); FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT OUTCOME; UNITED STATES;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; TREATMENT OUTCOME; UNITED STATES;

EID: 78649363138     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-8-77     Document Type: Review

References (30)

1. Wallace DJ, Hahn BH, . (Eds) Dubois' Lupus Erythematosus 2007, Philadelphia: Lippincott Williams & Wilkins, 7, (Eds).
2. Decker JL, Steinberg AD, Reinertsen JL, Plotz PH, Balow JE, Klippel JH. NIH conference: systemic lupus erythematosus: evolving concepts. Ann Intern Med 1979, 91:587-604.
3. U.S. Food and Drug Administration Guidance for Industry on Systemic Lupus Erythematosus: Developing Drugs for Treatment Accessed July 28, 2010. Also available at Federal Register 70(59):15868, March 29, 2005, U.S. Food and Drug Administration., http://www.fda.gov/ohrms/dockets/dockets/05d01-6/05d0106.htm
4. U.S. Food and Drug Administration Guidance for Industry on Systemic Lupus Erythematosus: Developing Medical Products for Treatment Accessed July 28, 2010, U.S. Food and Drug Administration., http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm
5. Yee CS, Farewell V, Isenberg DA, Prabu A, Sokoll K, Teh LS, Rahman A, Bruce IN, Griffiths B, Akil M, McHugh N, D'Cruz D, Khamashta MA, Bowman S, Maddison P, Zoma A, Allen E, Gordon C, . British Isles Lupus Assessment Group Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum 2006, 54:3300-3305. 10.1002/art.22162, 17009266, British Isles Lupus Assessment Group.
6. Wright SA, O'Prey FM, McHenry MT, Leahey WJ, Devine AB, Duffy EM, Johnston DG, Finch MB, Bell AL, McVeigh GE. A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann Rheum Dis 2008, 67:841-848. 10.1136/ard.2007.077156, 17875549.
7. Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M, . Canadian Network for Improved Outcomes in Systemic Lupus Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2008, 59:1796-1804. 10.1002/art.24068, 19035431, Canadian Network for Improved Outcomes in Systemic Lupus.
8. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D, . Aspreva Lupus Management Study Group Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009, 20:1103-1112. 10.1681/ASN.2008101028, 2678035, 19369404, Aspreva Lupus Management Study Group.
9. Wofsy D, Appel GB, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Solomons N, Lisk L. Aspreva Lupus Management Study maintenance results. Lupus 2010, 19(Suppl):27..
10. Lampropoulos CE, D'Cruz DP. Topical calcineurin inhibitors in systemic lupus erythematosus. Ther Clin Risk Manag 2010, 6:95-101. 10.2147/TCRM.S3193, 2857609, 20421909.
11. Remer CF, Weisman MH, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 2001, 10:480-483. 10.1191/096120301678416033, 11480845.
12. Sánchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, Wallace DJ, Ginzler EM, Sherrer YR, McIlwain HH, Freeman PG, Aranow C, Petri MA, Deodhar AA, Blanton E, Manzi S, Kavanaugh A, Lisse JR, Ramsey-Goldman R, McKay JD, Kivitz AJ, Mease PJ, Winkler AE, Kahl LE, Lee AH, Furie RA, Strand CV, Lou L, Ahmed M, Quarles B, Schwartz KE. Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. J Rheumatol 2008, 35:1567-1575.
13. Merrill JT, Burgos-Varagas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Raphupathi K, Peng LT, Kinasczuk M, Nash P. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of SLE: results of a 12-month exploratory study. Arthritis Rheum 2010, 62:377-387.
14. Boumpas DR, Furie R, Manzi S, Ilei GG, Wallace DJ, Balow JE, Vaishnaw A. A short course of BG9588 (anti-CD 40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003, 48:719-727. 10.1002/art.10856, 12632425.
15. Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy D, . IDEC-131 Lupus Study Group Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:3251-3258. 10.1002/art.10681, 12483729, IDEC-131 Lupus Study Group.
16. Czeloth N, Dalken B, Engling A, Osterroth F, Aigner S, Abufarag A, Wartenberg-Demand A, Koch H, Becker C, Jonuleit H, Daniel V, Haefeli WE, Schwarz A, Hass J, Wildemann B, Uherek C. Selective activation of naturally occurring T cells (Tregs) by the monoclonal antibody BT-061 as a novel therapeutic opportunity: preclinical and early clinical results. Annals Rheum Dis 2010, 69(S1):99.
17. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus. Arthritis Rheum 2010, 62:222-233. 10.1002/art.27233, 20039413.
18. Furie R, Looney RJ, Rovin B, Latinis KM, Appel G, Sanchez-Guerrero J, Fervenza FC, Maciuca R, Brunetta P, Zhang D, Garg J. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum 2009, 60:S429.
19. Wallace D, Kalunian K, Petri M, Strand V, Kilgallen B, Barry A, Gordon C. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM, a phase IIb study. Annals Rheum Dis 2010, 69(Suppl 3):558.
20. Wallace DJ, Stohl W, Furie RA, Lisse JR, Mc Kay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009, 61:1168-1178. 10.1002/art.24699, 2758229, 19714604.
21. Navarra S, Ilianova E, Bae SC, Guzman R, Tanasescu C, Gallacher A, Levy RA, Li EK, Thomas M, Jimenez R, Leon M, Hall S, Lan J, Kim HY, Pineda L, Zhong Z, Freimuth W, Petri M, . BLISS-52 Study Group Belimumab, a BlyS-specific inhibitor reduced disease activity, flares and steroid use in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 study. Annals Rheum Dis 2010, 69(S1). BLISS-52 Study Group.
22. Furie RA, Gladman D, d'Cruz D, Zamani O, Wallace D, von Vollenhoven R, Tegzova D, Merrill JT, Schwarting A, Clarke AE, Doria AE, Sanchez-Guerrero J, Chatham WW, Manzi S, Ginzler E, Mc KJ, Stohl W, Zhong ZJ, Hough D, Cooper SM, Freimuth W, Petri M, Belimumab. A BLyS specific inhibitor, reduced disease activity and severe flares with seropositive SLE: BLISS-76 study. Lupus 2010, 19S:13.
23. Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G, Smolen JS. Adverse events and efficacy of TNF-α blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009, 48:1451-1454. 10.1093/rheumatology/kep270, 19748965.
24. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010, 62:542-552. 10.1002/art.27221, 20112381.
25. Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD, . LJP 394-90-09 Investigator Consortium Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 2008, 58:2470-2480. 10.1002/art.23673, 18668592, LJP 394-90-09 Investigator Consortium.
26. Teva Pharmaceutical Industries Ltd.: Press release September 19, 2007. Accessed July 28, 2010., http://www.tevapharm.com/pr/2007/pr_689.asp
27. Weinblatt M, Kavanaugh A, Genovese M, Grossbard E, Magilavy D. Treatment of rheumatoid arthritis (RA) with an oral syk kinase inhibitor: A 6 month randomized placebo controlled phase 2b study in patients with active RA on chronic methotrexate. American College of Rheumatology 2009 annual scientific meeting, Abstract LB2 Accessed November 17, 2010., http://acr.confex.com/acr/2009/webprogram/Paper17160.html
28. Kaplan M. Eculizumab (Alexion). Curr Opin Investig Drugs 2002, 3:1017-1023.
29. Wallace DJ, Petri M, Olsen N, Kyriou K, Dennis G, Yao Y, Jallal B, Coyle A, Zeng L, White B. MEDI-545, an anti-interferon α monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus. Arthritis Rheum 2007, 56:S526.
30. Mc Bride J, Wallace DJ, Morimoto AY, Zhenling Y, Abbas A, Romeo M, Jiang J, Drappa J. Safety and pharmacodyamic response with administration of single and repeat doses of rontiluzmab in a phase I, placebo, controlled, double-blind, dose escalation study in SLE. Lupus 2010, 19S:15.